FDA cracks down on illegal ketamine sellers amid nearing ‘psychedelic revolution’
The US Food and Drug Administration’s (FDA’s) drug review agency has initiated a crackdown on e-commerce sites selling illicit ketamine…
08 Jul 2026
Kalohexis confidentially files IPO to back obesity and cachexia portfolio
Metabolic health-focused drug developer Kalohexis is eyeing a debut on the public market after confidentially filing for an initial public offering (IPO) – potentially adding it to a growing list…
08 Jul 2026
Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant
Novo Nordisk has taken an interest in a weight-loss implant developed by Californian medtech Vivani Medical, reflecting a broadening of the drugmaker’s strategy to fend off market rivals. Novo has…
08 Jul 2026
FDA grants rare paediatric designation to Vanda’s CMT2S therapy
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S). The…
08 Jul 2026
Biocytogen and Whitehawk partner to develop ADCs
Biocytogen and Whitehawk Therapeutics are set to develop bispecific antibody-drug conjugates (BsADCs), as part of a global partnership. Under this collaboration, Biocytogen will offer access to up to five bispecific…
07 Jul 2026
Merck KGaA-backed Cyllene Therapeutics secures €33m for gene therapy pipeline
Paris-based biotech Cyllene Therapeutics has raised €33m ($37.75m) to advance its pipeline of gene therapies headed by lead candidate EG110A for the treatment of severe neurogenic bladder conditions. The Series…
07 Jul 2026
Vertex signs agreement to acquire Crinetics for $10bn
Vertex has signed a definitive agreement to purchase Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired. Approved unanimously by both companies’ boards,…